Application of “Вetargin” in complex treatment of chronic hepatitis В in children with acute lymphoblastic leukemia


  • I.I. Nezgoda
  • L.V. Moroz
  • S. Singh
  • O.O. Singh
Keywords: сhronic hepatitis B, acute lymphoblastic leukemia, children, “Betargin”

Abstract

The aim of the study is to evaluate the effectiveness of the “Betargin” in the complex treatment of chronic hepatitis B (CHB) in children with cancer. We examined 39 children with chronic hepatitis B in the context of acute lymphoblastic leukemia (ALL) in the remission stage. The children were divided into 2 representative groups. Children of control group (17 patients) received base therapy with dietary nutrition, sorbents, enzyme. Patients in the main group (22 children) received the drug “Betargin” in addition to the base therapy. Clinical and laboratory parameters were evaluated, and the viral load was determined. In the course of scientific research, it was found that at the time of the examination and at the beginning of treatment, the characteristic biochemical changes in the blood of children with chronic hepatitis B and ALL were elevated liver cell enzymes (ALT, AST, AP) with normal values of total bilirubin count and its fractions. All patients without exception were in the stage of viral replication. The viral load ranged from 102 to 108 IU/ml. The treatment with “Betargin” improved liver cell enzymes and decrease AP. The use of “Betargin” in the treatment of chronic hepatitis B in children with ALL has improved detoxification function of the liver and normalized lipid metabolism. In the chronic viral hepatitis patients with cancer and without any possibility of antiviral therapy, it is recommended to use the “Betargin” (Farmatis, France) to improve the clinical symptoms of the disease and restore the basic functions of the liver.

References

1. Berezenko, V. S. (2007). Kliniko-patohenetychni osoblyvosti fibrohenezu pechinky pry khronichnykh hepatytakh u ditei ta shliakhy yoho medykamentoznoi korektsii. (Dys. d. med. nauk). Bv, Kyiv. [in Ukrainian].

2. Berezenko, V. S., & Tsarova, O. V. (2016). Kharakterystyka fibrozu pechinky u ditei z khronichnym virusnym hepatytom C za okremymy priamymy ta nepriamymy markeramy. Visnyk morfolohii, 22(1), 113-117. [in Ukrainian].

3. Boiko, A. E. (2000). Kliniko-imunolohichna kharakterystyka ditei z hostroiu limfoblastnoiu leikemiieiu ta khronichnym hepatytom B ta C. Onkolohiia, 2(1-2), 80-82. [in Ukrainian].

4. Inform. byulleten VOZ (2017). http://www.who.int/bulletin/volumes/95/ru/ [in Russian].

5. Kramarev, S. A., Doroshenko, V. A., Voronov, A. A., Evtushenko, V. V., Kilimnyuk, G. I., Shajda, E. V., & Agafonkina N. M. (2016). Virusnye gepatity B i C u detej s onkogematologicheskoj patologiej. Aktualnaya infektologiya, 10(1), 53-58. [in Russian].

6. Rejzis, A. R., & Nurmuhamedova, E. A. (2001). Klinicheskaya onkogematologiya. Moskva: GEOTAR. [in Russian].

7. Rejzis, A. R. (2002). Principy interferonoterapii virusnyh gepatitov u detej s onkogematologicheskimi zabolevaniyami. Voprosy gematologii / onkologii i immunopatologii v pediatrii, 1, 48-50. [in Russian].

8. Romanova, O. N., Kolomiec, N. D., & Gushina, L. M. (2013). Hronicheskie virusnye gepatity u detej so zlokachestvennymi novoobrazovaniyami. Klinicheskaya infektologiya. Parazitologiya, 5(2), 129-136. [in Russian].

9. Rossina, A. L., Smirnov, A. V., & Moiseenko E. I. (2003). Lechenie hronicheskih gepatitov V i S u detej s onkogematologicheskimi zabolevaniyami rekombinantnym interferonom a2v. Detskie infekcii, 1, 27-28. [in Russian].

10. Shadrin, O. H., Mahomedov, O. O., Cherneha, N. F., Basaraba, N. M., Diukareva, S. V., & Kovalchuk, A. A. (2014). Deiaki markery reheneratsii pechinky v ditei rannoho viku z urodzhenym i khronichnym hepatytom. Zdorove rebenka, 5, 7-12. [in Russian].

11. European Association for the study of the liver (2012). EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J. Hepatol., 2(30). doi: 10.1016/j.jhep.2012.02.010.

12. Golubovska, O. (2017) Local situation in Ukraine. 3rd Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV, 27-28 September 2017, Ljubljana, Slovenia / Reviews in Anviral therapy & Infectious Diseases 2017.

13. Mack, C. L., Gonzalez-Peralta, R. P., & Gupta N. (2012). NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents. J. Pediatr. Gastroenterol. Nutr., 6(54), 838-855. doi: 10.1097/MPG.0b013e318258328d.

14. Sokal, E. M., Paganelli, M., & Wirth, S. (2013). Management of chronic hepatitis B in childhood – ESPGHAN clinical practice guidelines. J. Hepatol. 4(59), 814-829. doi: 10.1016/j.jhep.2013.05.016.

15. Yazici, O., Sendur, M. A. N., & Aksoy, S. (2014). Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J. Gastroenterol., 22(20), 6716-6724. doi: 10.3748/wjg.v20.i22.6716.
Published
2017-10-27
How to Cite
Nezgoda, I., Moroz, L., Singh, S., & Singh, O. (2017). Application of “Вetargin” in complex treatment of chronic hepatitis В in children with acute lymphoblastic leukemia. Reports of Morphology, 23(2), 342-347. Retrieved from https://morphology-journal.com/index.php/journal/article/view/80
Section
ANTROPOLOGICAL STUDIES